Rational coupled dynamics network manipulation rescues disease-relevant mutant cystic fibrosis transmembrane conductance regulator

Citations Over TimeTop 10% of 2014 papers

Abstract

Many cellular functions necessary for life are tightly regulated by protein allosteric conformational change, and correlated dynamics between protein regions has been found to contribute to the function of proteins not previously considered allosteric. The ability to map and control such dynamic coupling would thus create opportunities for the extension of current therapeutic design strategy. Here, we present an approach to determine the networks of residues involved in the transfer of correlated motion across a protein, and apply our approach to rescue disease-causative mutant cystic fibrosis transmembrane regulator (CFTR) ion channels, ΔF508 and ΔI507, which together constitute over 90% of cystic fibrosis cases. We show that these mutations perturb dynamic coupling within the first nucleotide-binding domain (NBD1), and uncover a critical residue that mediates trans-domain coupled dynamics. By rationally designing a mutation to this residue, we improve aberrant dynamics of mutant CFTR as well as enhance surface expression and function of both mutants, demonstrating the rescue of a disease mutation by rational correction of aberrant protein dynamics.

Related Papers

• → Direct Comparison of the Functional Roles Played by Different Transmembrane Regions in the Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel Pore(2004)71 cited
• → An unstable transmembrane segment in the cystic fibrosis transmembrane conductance regulator(1999)63 cited
• → 68 The physiological state of Pseudomonas aeruginosa populations in lungs of Cystic Fibrosis (CF) patients(2006)
• → 40 Longitudinal values of sweat chloride concentration among infants identified by cystic fibrosis (CF) newborn screening (NBS) in California(2013)
• → P181 Pseudomonas rates post cystic fibrosis transmembrane conductance regulator (CFTR) modulators and outcomes in those stopping inhaled antibiotics(2024)